Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis
The Medical Letter on Drugs and Therapeutics · 2024
DOI: 10.58347/tml.2024.1701a ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2024. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Pyridazines, Uracil. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Resmetirom (Rezdiffra – Madrigal), a thyroid hormone receptor-beta agonist, has received accelerated approval from the FDA for treatment of noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis in adults.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
(2024). Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2024.1701a
Vancouver
Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis. The Medical Letter on Drugs and Therapeutics. 2024. doi:10.58347/tml.2024.1701a
BibTeX
@article{euvimed2024,
title = {Resmetirom (Rezdiffra) for Metabolic Dysfunction-Associated Steatohepatitis},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2024},
doi = {10.58347/tml.2024.1701a}
}
EUVIMED